Sit Less, Interact and Move More (SLIMM) 2 Study

Description

* Prolonged sitting (sedentary behavior) is a risk factor for decreased kidney function, obesity, diabetes and mortality. Prolonged sitting is associated with decreased kidney function and increased risk of diabetes, heart disease and death. * In a previous pilot study funded by NIH, it was shown that a Sit Less, Interact and Move More (SLIMM) intervention targeting sedentary behavior in people with kidney disease was able to decrease prolonged sitting but that effect was not sustained. * Therefore, the researchers are currently conducting a follow-up study named Sit Less, Interact and Move More (SLIMM) 2. * This NIH funded study is conducted at the University of Utah and Stanford University. * The purpose of this study is to see if guided resistance training (to improve muscle strength) and semaglutide (FDA approved diabetes and weight loss medication that might also improve physical function) can boost adherence to the SLIMM Intervention and reduce sedentary behavior.

Conditions

Chronic Kidney Diseases, Obesity

Talk to us

Study Overview

On this page

Study Details

Study overview

* Prolonged sitting (sedentary behavior) is a risk factor for decreased kidney function, obesity, diabetes and mortality. Prolonged sitting is associated with decreased kidney function and increased risk of diabetes, heart disease and death. * In a previous pilot study funded by NIH, it was shown that a Sit Less, Interact and Move More (SLIMM) intervention targeting sedentary behavior in people with kidney disease was able to decrease prolonged sitting but that effect was not sustained. * Therefore, the researchers are currently conducting a follow-up study named Sit Less, Interact and Move More (SLIMM) 2. * This NIH funded study is conducted at the University of Utah and Stanford University. * The purpose of this study is to see if guided resistance training (to improve muscle strength) and semaglutide (FDA approved diabetes and weight loss medication that might also improve physical function) can boost adherence to the SLIMM Intervention and reduce sedentary behavior.

Sit Less, Interact and Move More (SLIMM) 2 Study

Sit Less, Interact and Move More (SLIMM) 2 Study

Condition
Chronic Kidney Diseases
Intervention / Treatment

-

Contacts and Locations

Stanford

Stanford University, Stanford, California, United States, 94305

Salt Lake City

University of Utah, Salt Lake City, Utah, United States, 84108

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) Glomerular Filtration Rate (eGFR) 20 to \<60 mL/min/1.73m\^2
  • * Able to perform resistance training
  • * Access to compatible "smartphone" or device (i.e., Android, Kindle or Apple with internet connectivity or mobile network), desktop or laptop
  • * Type 1 Diabetes
  • * History of gastroparesis or paralytic ileus
  • * At baseline, if sedentary time is 25 min/hr or less, measured by accelerometer
  • * Potential contraindications to semaglutide such as a history of pancreatitis, and a family or personal history of multiple endocrine neoplasia type 2 or familial medullary thyroid carcinoma.
  • * Previous bariatric surgery
  • * Medical condition likely to limit survival to less than 1 year
  • * Anticipated start of dialysis or kidney transplantation within 6 months
  • * Any factors judged by the investigator or study team to likely limit adherence to interventions
  • * Vulnerable populations- pregnant or incarcerated
  • * Enrolled in interventional trials using drugs or devices
  • * Not able to undergo informed consent
  • * Recent hospitalizations or major interventional procedures done within the past 60 days
  • * Known or suspected hypersensitivity to tegaderm
  • * Use of any GLP-1 receptor agonist within 30 days prior to screening
  • * Presently classified as being in New York Heart Association (NYHA) Class IV Heart Failure
  • * Daytime use of supplemental oxygen (i.e., prescribed a stationary or portable oxygen system)
  • * Presence of metastatic cancer
  • * Current use of mobility aid(s)
  • * Living in the same household of a participant already enrolled in the study

Ages Eligible for Study

20 Years to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

Srinvasan Beddhu,

Srinivasan Beddhu, M.D., PRINCIPAL_INVESTIGATOR, University of Utah

Study Record Dates

2027-03-31